- Home
- NBH vs PHAT Comparison
NBH vs PHAT Comparison
Compare NBH & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- PHAT
- Stock Information
- Founded
- NBH 2002
- PHAT 2018
- Country
- NBH United States
- PHAT United States
- Employees
- NBH N/A
- PHAT N/A
- Industry
- NBH Finance/Investors Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- PHAT Health Care
- Exchange
- NBH Nasdaq
- PHAT Nasdaq
- Market Cap
- NBH 288.5M
- PHAT 289.0M
- IPO Year
- NBH N/A
- PHAT 2019
- Fundamental
- Price
- NBH $9.87
- PHAT $4.25
- Analyst Decision
- NBH
- PHAT Strong Buy
- Analyst Count
- NBH 0
- PHAT 4
- Target Price
- NBH N/A
- PHAT $16.25
- AVG Volume (30 Days)
- NBH 85.9K
- PHAT 2.2M
- Earning Date
- NBH 01-01-0001
- PHAT 05-01-2025
- Dividend Yield
- NBH 4.34%
- PHAT N/A
- EPS Growth
- NBH N/A
- PHAT N/A
- EPS
- NBH 0.12
- PHAT N/A
- Revenue
- NBH N/A
- PHAT $81,859,000.00
- Revenue This Year
- NBH N/A
- PHAT $195.45
- Revenue Next Year
- NBH N/A
- PHAT $106.76
- P/E Ratio
- NBH $87.04
- PHAT N/A
- Revenue Growth
- NBH N/A
- PHAT 3055.70
- 52 Week Low
- NBH $8.75
- PHAT $2.21
- 52 Week High
- NBH $11.01
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- NBH 39.25
- PHAT 54.83
- Support Level
- NBH $9.86
- PHAT $3.92
- Resistance Level
- NBH $9.99
- PHAT $4.35
- Average True Range (ATR)
- NBH 0.11
- PHAT 0.40
- MACD
- NBH -0.01
- PHAT 0.13
- Stochastic Oscillator
- NBH 17.39
- PHAT 85.63
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.